436 related articles for article (PubMed ID: 32744123)
1. Fumarate hydratase as a therapeutic target in renal cancer.
Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
[TBL] [Abstract][Full Text] [Related]
2. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals.
Forde C; Lim DHK; Alwan Y; Burghel G; Butland L; Cleaver R; Dixit A; Evans DG; Hanson H; Lalloo F; Oliveira P; Vialard L; Wallis Y; Maher ER; Woodward ER
Eur Urol Oncol; 2020 Dec; 3(6):764-772. PubMed ID: 31831373
[TBL] [Abstract][Full Text] [Related]
3. Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer.
Shuch B; Li S; Risch H; Bindra RS; McGillivray PD; Gerstein M
Cancer; 2020 Aug; 126(16):3657-3666. PubMed ID: 32413184
[TBL] [Abstract][Full Text] [Related]
4. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
Sanz-Ortega J; Vocke C; Stratton P; Linehan WM; Merino MJ
Am J Surg Pathol; 2013 Jan; 37(1):74-80. PubMed ID: 23211287
[TBL] [Abstract][Full Text] [Related]
5. Renal cell carcinoma in young FH mutation carriers: case series and review of the literature.
Hol JA; Jongmans MCJ; Littooij AS; de Krijger RR; Kuiper RP; van Harssel JJT; Mensenkamp A; Simons M; Tytgat GAM; van den Heuvel-Eibrink MM; van Grotel M
Fam Cancer; 2020 Jan; 19(1):55-63. PubMed ID: 31792767
[TBL] [Abstract][Full Text] [Related]
6. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ
Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760
[TBL] [Abstract][Full Text] [Related]
7. Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.
Kamai T; Abe H; Arai K; Murakami S; Sakamoto S; Kaji Y; Yoshida KI
BMC Cancer; 2016 Mar; 16():232. PubMed ID: 26983443
[TBL] [Abstract][Full Text] [Related]
8. Complexities in estimating the true risk of hereditary leiomyomatosis and renal cell carcinoma and the development of kidney cancer.
Ball MW; Ricketts CJ
Cancer; 2020 Aug; 126(16):3617-3619. PubMed ID: 32413160
[No Abstract] [Full Text] [Related]
9. Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer.
Stewart L; Glenn GM; Stratton P; Goldstein AM; Merino MJ; Tucker MA; Linehan WM; Toro JR
Arch Dermatol; 2008 Dec; 144(12):1584-92. PubMed ID: 19075141
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients.
Choi Y; Keam B; Kim M; Yoon S; Kim D; Choi JG; Seo JY; Park I; Lee JL
Cancer Res Treat; 2019 Oct; 51(4):1549-1556. PubMed ID: 30913859
[TBL] [Abstract][Full Text] [Related]
11. Expanding morphological and clinical aspects of hereditary leiomyomatosis and renal cell carcinoma (HLRCC): a case report in a patient with unusual morphology and clinical presentation.
da Cunha IW; da Costa WH; Morini MA; Bezerra SM; Carraro DM; Torrezan GT; Formiga MNC; Guimaraes GC; Zequi SC; Soares FA
Virchows Arch; 2018 Dec; 473(6):775-779. PubMed ID: 30171332
[TBL] [Abstract][Full Text] [Related]
12. Utility of prospective pathologic evaluation to inform clinical genetic testing for hereditary leiomyomatosis and renal cell carcinoma.
Kopp RP; Stratton KL; Glogowski E; Schrader KA; Rau-Murthy R; Russo P; Coleman JA; Offit K
Cancer; 2017 Jul; 123(13):2452-2458. PubMed ID: 28171700
[TBL] [Abstract][Full Text] [Related]
13. Germline Whole-Gene Deletion of FH Diagnosed from Tumor Profiling.
Ueki A; Sugano K; Misu K; Aimono E; Nakamura K; Tanishima S; Tanaka N; Mikami S; Hirasawa A; Ando M; Yoshida T; Oya M; Nishihara H; Kosaki K
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360727
[TBL] [Abstract][Full Text] [Related]
14. Hereditary leiomyomatosis and renal cell carcinoma syndrome associated uterine smooth muscle tumors: Bridging morphology and clinical screening.
Garg K; Rabban J
Genes Chromosomes Cancer; 2021 Mar; 60(3):210-216. PubMed ID: 33099845
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and molecular features of hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinomas.
Furuya M; Iribe Y; Nagashima Y; Kambe N; Ohe C; Kinoshita H; Sato C; Kishida T; Okubo Y; Numakura K; Nanjo H; Nakaigawa N; Makiyama K; Hasumi H; Iwashita H; Ohta J; Kitamura H; Nakajima T; Yoshida T; Nakagawa M; Tanaka R; Yao M
J Clin Pathol; 2020 Dec; 73(12):819-825. PubMed ID: 32376712
[TBL] [Abstract][Full Text] [Related]
16. Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report.
Iribe Y; Furuya M; Shibata Y; Yasui M; Funahashi M; Ota J; Iwashita H; Nagashima Y; Hasumi H; Hayashi N; Makiyama K; Kondo K; Tanaka R; Yao M; Nakaigawa N
Fam Cancer; 2021 Jan; 20(1):75-80. PubMed ID: 32666341
[TBL] [Abstract][Full Text] [Related]
17. A Clinicopathological and Molecular Analysis of Fumarate Hydratase (FH)-deficient Renal Cell Carcinomas with Heterogeneous Loss of FH Expression.
Anderson WJ; Tsai HK; Sholl LM; Hirsch MS
Int J Surg Pathol; 2022 Sep; 30(6):606-615. PubMed ID: 35048731
[No Abstract] [Full Text] [Related]
18. Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma.
Zhang L; Walsh MF; Jairam S; Mandelker D; Zhong Y; Kemel Y; Chen YB; Musheyev D; Zehir A; Jayakumaran G; Brzostowski E; Birsoy O; Yang C; Li Y; Somar J; DeLair D; Pradhan N; Berger MF; Cadoo K; Carlo MI; Robson ME; Stadler ZK; Iacobuzio-Donahue CA; Joseph V; Offit K
Hum Mutat; 2020 Jan; 41(1):103-109. PubMed ID: 31444830
[TBL] [Abstract][Full Text] [Related]
19. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.
Muller M; Ferlicot S; Guillaud-Bataille M; Le Teuff G; Genestie C; Deveaux S; Slama A; Poulalhon N; Escudier B; Albiges L; Soufir N; Avril MF; Gardie B; Saldana C; Allory Y; Gimenez-Roqueplo AP; Bressac-de Paillerets B; Richard S; Benusiglio PR
Clin Genet; 2017 Dec; 92(6):606-615. PubMed ID: 28300276
[TBL] [Abstract][Full Text] [Related]
20. [Hereditary leiomyomatosis and renal cell cancer - HLRCC/multiple cutaneous and uterine leimomyomatosis - MCUL].
Plevová P; Hladíková A; Tesařová M
Klin Onkol; 2012; 25 Suppl():S55-8. PubMed ID: 22920208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]